Avadomide - Celgene Corporation
Alternative Names: CC 122Latest Information Update: 08 Oct 2024
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Juno Therapeutics
- Class Antineoplastics; Piperidones; Quinazolines
- Mechanism of Action CRBN protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma
- Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Liver cancer; Non-Hodgkin's lymphoma
- Phase I Solid tumours
- No development reported Glioblastoma; Multiple myeloma
Most Recent Events
- 08 Oct 2024 Celgene terminates a phase I trial in Solid tumours (Late-stage disease) in Japan das it is replaced with another clinical trial (NCT02509039)
- 06 May 2024 Celgene terminates a phase I trial in Non-Hodgkin lymphoma (Late-stage disease) in Japan das it is replaced with another clinical trial (NCT02509039)
- 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)